Small Molecules
Total Trials
19
As Lead Sponsor
17
As Collaborator
2
Total Enrollment
6,057
NCT01108783
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
Phase: Phase 3
Role: Lead Sponsor
Start: Apr 30, 2003
Completion: Feb 29, 2004
NCT01127620
Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
Start: May 31, 2004
Completion: Nov 30, 2006
NCT00504933
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
Start: May 31, 2005
Completion: Nov 30, 2005
NCT00421109
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Start: Jul 31, 2006
Completion: Jul 31, 2007
NCT00419783
A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
Phase: Phase 1
Start: Aug 31, 2006
Completion: Dec 31, 2006
NCT00420082
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
Phase: Phase 2
Start: Oct 31, 2006
NCT00574210
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
Start: Oct 31, 2007
Completion: Feb 29, 2008
NCT00572611
Human Mass Balance Study With Bilastine
Start: Nov 30, 2007
Completion: Dec 31, 2007
NCT00574379
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Start: Dec 31, 2007
Completion: Mar 31, 2008
NCT01081574
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
Phase: Phase 1/2
Start: Jan 31, 2010
Completion: Jun 30, 2012
NCT01124123
Oral Bioavailability of Bilastine
Start: May 31, 2010
Completion: Sep 30, 2010
NCT01271075
Bilastine Updosing - Characterization of Underlying Mechanisms
Phase: Phase 2/3
Role: Collaborator
Start: Sep 30, 2010
Completion: Dec 31, 2011
NCT03231969
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Start: Jul 20, 2017
Completion: Oct 11, 2017
NCT03479307
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
Start: Apr 7, 2018
Completion: Aug 10, 2018
NCT04366908
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Start: May 7, 2020
Completion: Apr 19, 2022
NCT04735926
Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
Start: Dec 23, 2020
Completion: Apr 25, 2023
NCT04810390
Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
Start: Mar 26, 2021
Completion: Nov 30, 2022
NCT05788497
Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids
Start: Mar 30, 2023
Completion: Jan 4, 2024
NCT06176560
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
Start: Mar 31, 2024
Completion: Aug 31, 2025
Loading map...